Results 181 to 184 of about 8,600 (184)

Non‐Hydroxamate Inhibitors of IspC Enzyme in the MEP Pathway: Structural Insights and Drug Development Potential

Chemical Biology & Drug Design
ABSTRACT1‐Deoxy‐D‐xylulose‐5‐phosphate reductoisomerase (IspC) is a key enzyme in the MEP pathway, essential for many bacteria, human pathogens, and plants, thus being an attractive drug target. Fosmidomycin, a potent IspC inhibitor with hydroxamate metal‐binding pharmacophores (MBPs), has entered clinical trials for malaria but is hampered by ...
Yaqing, Zhou, Jili, Wang, Yong, Sun, Yarui, Cheng, Wenhai, Wu   +4 more
openaire   +2 more sources

Chemosensitization of non-small cell lung cancer to sorafenib via non-hydroxamate s-triazinedione-based MMP-9/10 inhibitors

Bioorganic Chemistry
Non-small cell lung cancer (NSCLC) continues to be a leading cause of cancer death. Its fatality is associated with angiogenesis and metastasis. While VEGFR inhibitors are expected to be the central pillar for halting lung cancer, several clinical reports declared their subpar activities as monotherapy.
Hosam H, Khalil, Mohamed M, El-Sheshtawy, Sherine N, Khattab, Marwa M, Abu-Serie, Michael G, Shehat, Mohamed, Teleb, Nesreen S, Haiba   +6 more
openaire   +2 more sources

Characteristics of novel non-hydroxamate inhibitors of histone deacetylases

European Journal of Cancer, 2002
openaire   +1 more source

Multiple virtual screening approaches to identify novel, non-hydroxamic class-I HDAC inhibitors.

2007
AGAMENNONE, Mariangela, A. Bakker, E. Dalla Pozza, A. Padova   +3 more
openaire   +1 more source